Salivary Immune Responses to the 7-Valent Pneumococcal Conjugate Vaccine in the First 2 Years of Life

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Rodenburg, Gerwin D ^a   Sanders, Elisabeth A M ^a   van Gils, Elske J M ^a,b   Veenhoven, Reinier H ^b   Zborowski, Tomasz ^a   van den Dobbelsteen, Germie P J M ^c   Bloem, Andries C ^d   Berbers, Guy A M ^c   Bogaert, Debby ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Orthopaedic Surgery   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; INFANT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SALIVA LEVEL; SEROTYPING; VACCINATION;

ANTIBODY FORMATION; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SALIVA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84867612722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046916     Document Type: Article

References (30)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187-195.
2. Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, et al. (2010) Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16: 816-823.
3. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344: 403-409.
4. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, et al. (2009) Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302: 159-167.
5. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, et al. (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196: 1211-1220.
6. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, et al. (2006) Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 13: 165-169.
7. Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, et al. (2008) Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis 197: 1511-1518.
8. Soininen A, Pursiainen H, Kilpi T, Kayhty H, (2001) Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis 184: 569-576.
9. Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH, (2004) Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 190: 545-550.
10. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, et al. (2005) Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 192: 387-393.
11. Millar EV, O'Brien KL, Bronsdon MA, Madore D, Hackell JG, et al. (2007) Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 44: 1173-1179.
12. Fasching CE, Grossman T, Corthesy B, Plaut AG, Weiser JN, et al. (2007) Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect Immun 75: 1801-1810.
13. Finn A, Zhang Q, Seymour L, Fasching C, Pettitt E, et al. (2002) Induction of functional secretory IgA responses in breast milk, by pneumococcal capsular polysaccharides. J Infect Dis 186: 1422-1429.
14. Simell B, Melin M, Lahdenkari M, Briles DE, Hollingshead SK, et al. (2007) Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. J Infect Dis 196: 1528-1536.
15. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, et al. (2001) Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 20: 25-33.
16. Nurkka A, Lahdenkari M, Palmu A, Kayhty H, (2004) Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial. Vaccine 23: 298-304.
17. Bogaert D, Veenhoven RH, Ramdin R, Luijendijk IH, Rijkers GT, et al. (2005) Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media. Vaccine 23: 2607-2613.
18. Zhang Q, Arnaoutakis K, Murdoch C, Lakshman R, Race G, et al. (2004) Mucosal immune responses to capsular pneumococcal polysaccharides in immunized preschool children and controls with similar nasal pneumococcal colonization rates. Pediatr Infect Dis J 23: 307-313.
19. Korkeila M, Lehtonen H, Ahman H, Leroy O, Eskola J, et al. (2000) Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 18: 1218-1226.
20. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, et al. (2002) A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 117: 589-596.
21. Rodenburg GD, van Gils EJ, Veenhoven RH, Jones N, Tcherniaeva I, et al. (2010) Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine 28: 1391-1396.
22. Melkert HE, Gerritsen AMM, Hahné SJM, (2007) The National Immunisation Programme in the Netherlands Developments in 2006.
23. Simell B, Kilpi TM, Kayhty H, (2002) Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children. J Infect Dis 186: 1106-1114.
24. Lee CJ, Koizumi K, Henrichsen J, Perch B, Lin CS, et al. (1984) Capsular polysaccharides of nongroupable streptococci that cross-react with pneumococcal group 19. J Immunol 133: 2706-2711.
25. Lee CJ, Koizumi K, (1981) Immunochemical relations between pneumococcal group 19 and Klebsiella capsular polysaccharides. J Immunol 127: 1619-1623.
26. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, et al. (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25: 3816-3826.
27. Musher DM, Watson DA, Baughn RE, (2000) Genetic control of the immunologic response to pneumococcal capsular polysaccharides. Vaccine 19: 623-627.
28. Goldblatt D, Southern J, Ashton L, Andrews N, Woodgate S, et al. (2009) Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom. Pediatr Infect Dis J.
29. Brandtzaeg P, (2007) Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann N Y Acad Sci 1098: 288-311.
30. Prevaes SM, van Wamel WJ, de Vogel CP, Veenhoven RH, van Gils EJ, et al. (2012) Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage. Infect Immun.